<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Top 12 Questions: Applications of PDXO

Q&A on utilities of PDX-Derived Organoids, PDXO

Q&A on utilities of PDX-Derived Organoids, PDXOReview the top 12 questions on PDX-derived organoid (PDXO) utilities from our recent webinar, answered by Dr. Rajendra Kumari, Global Head of Scientific Communication.

High-Throughput Screening using PDXO

In the HTS do you Seed Organoids with Matrigel® or BME or do you use Special Plates?

This is performed with Matrigel.

How many PDXO per Cancer Type do you Recommend to Test when Screening a Compound to have a Reproducible and Robust Result?

The number of models per cancer type will be driven by a number of different factors including how many models are currently available. Our collection is rapidly expanding and we can also provide statistical advice where required.

What is the Standard Length for Compound Testing in PDXO Screening?

Typically, 5 days’ incubation with test agents

Immunological and TME Evaluation with PDXO

How do you use PDXO to Mimic Immunological Interaction of the TME

You can perform co-cultures with immune cells, we have some preliminary studies looking at optimal conditions and assay duration for T cell mediated killing of the organoids. The data will be shared when the protocol is fully established.

For the Different PDXO models, have you Classified According to Cold and Immune Inflamed Tumors, or How Immune Populations Change during Culture and Expansion?

There are no immune cells within the PDXO culture, as the conditions propagate organoids of epithelial origin with the HUB methods. Any immune cells are specifically co-cultured.

You Mentioned that these Organoids can be Grown in Co-Culture with Other Cell Types including Immune Cells. Do you use Patient Matched Immune Cells? Do you have any Validation using Organoids + Immune Cells with I/O Target Modulating Drugs?

We are still developing the co-culture conditions and some of this was presented in our recent EORTC poster. We use healthy PBMCs pre-activated with anti-CD3 and anti-CD28 for 3 days before co-culture with PDXO and validation with immunotherapies is still ongoing. We don’t have autologous PBMCs for the PDXOs - where new PDOs are developed this may be possible.

General PDXO Utilities

Would the PDXO Approach be Feasible When it comes to Personalized Cancer Therapy, or would it take Too Long to Generate the Mouse Model etc.?

The purpose of the PDXO is not for use as a personalized medicine approach but to generate a large library of organoid models for population studies in preclinical research.

Have you Tested Viral Infection of Organoids? (AAV, oncolytic) for Cancer Gene Therapy Applications?

We haven’t done this yet. We hope to pursue this, and are looking at lentiviral transduction initially.

Do you know of any Biobank of Non Tumor Derived Organoids? Organoids Generated from Normal Tissues?

Yes, there are biobanks for normal organoids - we have access to the normal organoids from Hubrecht Organoid Technology (HUB).

Can Cell Lines be Developed from Organoids?

This is not something we have tried.

Is There a Reason that Colorectal Organoids are More Often Used than Organoids from Other Cell Types (e.g. Head and Neck Cancer)?

There is a lot more research using colorectal organoids, and therefore understanding, due to the original protocols developed in the Clevers lab.

How many Divisions do Your PDXO model CSCs undergo in Drug Testing?

This is something that we haven’t look at yet.

Read our other posts to understand more PDXO key questions around model development and correlation with PDX/patient tumors.


Related Posts